Meeting of the regional Green Light Committee for Europe and workshop on introduction of new medicines for drug-resistant tuberculosis treatment
25–27 July 2017 Copenhagen, Denmark
In response to the need to consolidate the efforts to address tuberculosis (TB) and multidrug-resistant TB (MDR-TB) in the WHO European Region, the regional Green Light Committee for Europe (rGLC/Europe) was established in 2010. The rGLC/Europe serves as an independent advisory board on multidrug and extensively drug resistant TB (M/XDR-TB), hosted by the WHO Regional Office for Europe. rGLC/Europe has been playing an essential role in implementation and development of the practical approaches of the End TB Strategy, with the specific role of fine tuning the tasks and steps to be taken on M/XDR-TB diagnostics, treatment, prevention and follow-up. Regular meetings of rGLC/Europe members are held via WebEx and Skype, and twice a year the Regional Office organizes face-to-face meetings of the members, and invites the relevant stakeholders to assure transparency and accountability. This year the meeting will start with a workshop for consultants on the use of new medicines and shorter treatment regimens recommended by WHO for the treatment of drug-resistant TB.
The overall objective of the workshop and rGLC meeting is to update the members and consultants on the latest developments, in line with WHO global and regional policies, guidance and plans. The specific objective of the meeting is to update and align regional policies, treatment strategies, regimens and medications with WHO global recommendations.